For a patient with lenalidomide-refractory R/R multiple myeloma at first or second relapse, how would MeziKd (if approved based on SUCCESSOR-2) factor into your sequencing decision relative to BCMA-directed and other available options?

There is never a good time to be a myeloma patient, but this is the best time it has ever been.

Tldr; I would still prefer a BCMA-directed strategy for patients with BCMA-naive relapsed MM.

The recently reported results of the phase 3 SUCCESSOR-2 trial demonstrated the efficacy of mezigdomide, a novel...